Alzheimer’s Patient Groups Put Pressure on U.S. to Pay for Biogen Drug

An advertisement aimed at loosening proposed restrictions on new Alzheimer’s treatments is seen in this undated handout image. UsAgainstAlzheimer?s Action/Handout via REUTERS

Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television and local advertisements that began running during the Sunday morning political shows.

The unusual ad campaign comes after a high-profile disagreement between government health agencies over who should have access to Biogen’s (BIIB.O) Aduhelm, the first treatment for the mind-wasting disease to be approved in 20 years.

The government’s Medicare program, which provides health benefits for Americans aged 65 and older, in January proposed paying for Biogen’s drug and similar treatments in development only for patients enrolled in years-long government studies.

Click here to read more.

SOURCE: Reuters – Reporting By Deena Beasley Editing by Caroline Humer and Bill Berkrot